Evidence map›Paper›PMID 28835659›Full record

Trial reportScientific reports2017

Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India.

Edward P K Parker, Ira Praharaj, Jacob John, Saravanakumar Puthupalayam Kaliappan, Beate Kampmann, Gagandeep Kang, Nicholas C Grassly

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 7 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 7 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Global Microbiome: Core and Unique Signatures Across Diverse Populations.International journal of molecular sciences · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Effect of one prophylactic dose of azithromycin on Bifidobacterium infantis colonization in infants from the Mumta trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Edward P K ParkerDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK. edward.parker@imperial.ac.uk.
Ira PraharajChristian Medical College, Vellore, Tamil Nadu, India.ORCID 0000-0002-0541-1146
Jacob JohnChristian Medical College, Vellore, Tamil Nadu, India.
Saravanakumar Puthupalayam KaliappanChristian Medical College, Vellore, Tamil Nadu, India.ORCID 0000-0002-1904-6880
Beate KampmannDepartment of Paediatrics, Imperial College London, London, UK.
Gagandeep KangChristian Medical College, Vellore, Tamil Nadu, India.
Nicholas C GrasslyDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK.
Christian Medical College, Vellore · INImperial College London · GBMRC Unit the Gambia · GM

Funding

Medical Research Council
6 · The paper itself

Abstract

Macrolides are among the most widely prescribed antibiotics worldwide. However, their impact on the gut's bacterial microbiota remains uncertain. We characterised the intestinal microbiota in 6-11 month-old infants in India who received a 3-day course of azithromycin or placebo during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588). In 60 infants per study arm, we sequenced the V4 region of the bacterial 16S rRNA gene in stool samples collected before and 12 days after finishing treatment. We also tested for the presence of common bacterial, viral, and eukaryotic enteropathogens in the same samples using real-time PCR in a Taqman array card (TAC) format. Azithromycin induced a modest decline in microbiota richness and a shift in taxonomic composition driven by a reduction in the relative abundance of Proteobacteria and Verrucomicrobia (specifically Akkermansia muciniphila). The former phylum includes pathogenic strains of Escherichia coli and Campylobacter spp. that declined in prevalence based on the TAC assay. These findings differ from previous observations among older children and adults in Europe and North America, suggesting that the effects of azithromycin on the bacterial microbiota may be specific to the age and geographic setting of its recipients.

Indexed as

Age FactorsAnti-Bacterial AgentsAzithromycinBacteriaBacterial InfectionsBiodiversityFemaleGastroenteritisGastrointestinal MicrobiomeHumansIndiaInfantInfant, NewbornMaleMetagenomeMetagenomicsAnti-Bacterial AgentsAzithromycin

Identifiers

PMID28835659
PMCPMC5569098
OpenAlexW2746957850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.